Clinical Trial Update: Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial to assess the efficacy, pharmacokinetics, safety, and tolerability of iptacopan in children with primary IgA nephropathy; recruitment is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Status: RECRUITING